G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response
Naval Daver,Sreyashi Basu,Guillermo Garcia-Manero,Hussein A. Abbas,Marina Konopleva,Tapan M. Kadia,Courtney D. DiNardo,Gautam Borthakur,Ahmad S. Alotaibi,Naveen Pemmaraju,Elias Jabbour,Sherry Pierce,Mark Brandt,Koichi Takahashi,Jing Ning,Steven M. Kornblau,Koji Sasaki,Musa Yilmaz,Ghayas C. Issa,Nicholas J. Short,Jairo Matthews,Wilmer Flores,Michael Andreeff,Jorge E. Cortes,Farhad Ravandi,James P. Allison,Hagop M. Kantarjian,Padmanee Sharma +27 more
TL;DR: AZA+Nivo induced novel and expanded T cell clonotypes, almost exclusively in Rs, which may be a pre-requisite of response to PD1 based therapies, as PD1 inhibitors have limited ability to mobilize peripheral T-cells.
Journal ArticleDOI
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned.
Esther Oliva,Uwe Platzbecker,Pierre Fenaux,Guillermo Garcia-Manero,Thomas W. LeBlanc,Bhumika J. Patel,Anne Sophie Kubasch,Mikkael A. Sekeres +7 more
TL;DR: In this paper, the authors describe the limitations of measuring HRQoL in patients with myelodysplastic syndromes and provide some recommendations to improve the measurement of this outcome in future trials.
Journal ArticleDOI
Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations
Iman Aboudalle,Hagop M. Kantarjian,Maro Ohanian,Yesid Alvarado,Elias Jabbour,Guillermo Garcia-Manero,Kiran Naqvi,William G. Wierda,Naval Daver,Jan A. Burger,Marina Konopleva,Koichi Takahashi,Michael Andreeff,Naveen Pemmaraju,Alessandra Ferrajoli,Gautam Borthakur,Tapan M. Kadia,Farhad Ravandi,Jorge E. Cortes +18 more
TL;DR: The primary objective was to determine the dose limiting toxicity (DLT) and maximal tolerated dose of crenolanib-based combinations, as well as overall response rates (ORR), including complete remission (CR), CR with incomplete blood count recovery (CRi), and partial remission (PR).
Journal ArticleDOI
A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.
Naval Daver,Arturo Vega-Ruiz,Hagop M. Kantarjian,Zeev Estrov,Alessandra Ferrajoli,Steve Kornblau,Srdan Verstovsek,Guillermo Garcia-Manero,Jorge E. Cortes +8 more
TL;DR: A phase II pilot study of homoharringtonine in myelodysplastic syndrome finds that it might have clinical activity in some patients with MDS.
Journal ArticleDOI
Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) ≥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).
Stefan Faderl,Farhad Ravandi,Alessandra Ferrajoli,Guillermo Garcia-Manero,Zeev Estrov,Deborah A. Thomas,Susan O'Brien,Srdan Verstovsek,William G. Wierda,Jorge E. Cortes,Francis J. Giles,Monica Kwari,Rita Jarmon,Hagop M. Kantarjian +13 more
TL;DR: A lower dose schedule of clofarabine +/− low-dose ara-C (LDAC) in pts ≥ 60 yrs and previously untreated AML shows activity in older pts with AML, and its role in elderly AML induction needs to be evaluated further.